Patents by Inventor Patrick Daniel Matthias

Patrick Daniel Matthias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200216563
    Abstract: The present application provides a HDAC6 inhibitor for use in treating a degenerative disease associated with the formation of intracellular granules, wherein said granules are formed by the aggregation of a protein selected from the group comprising APP, Tau, Ataxin-2, hnRNPA1, C9orf72, Lamin A/C, Myotilin, Matrin 3, alpha-synuclein, SOD1, FUS, hnRNPA2B1, VCP, TIA1, Desmin and Huntingtin, and wherein said inhibitor inhibits both the CD1 and CD2 of HDAC6.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 9, 2020
    Inventors: Patrick Daniel Matthias, Makoto Saito
  • Publication number: 20150184154
    Abstract: The present application provides a method for treating a neurodegenerative disease in a subject characterised in that a therapeutically effective amount of a modulator of HDAC6 administered to said subject.
    Type: Application
    Filed: July 3, 2013
    Publication date: July 2, 2015
    Inventors: Gabriele Matthias, Patrick Daniel Matthias, Oliver TrĂ¼e
  • Publication number: 20040191756
    Abstract: Homozygouse knock-out mice lacking the Aiolos gene are shown to exhibit multiple phenotypes in common with humans suffering from the autoimmune disease Systemic Lupus Erythematosus (SLE). When Aiolos −/− mice are crossed with homozygous knock out mice lacking the OBF-1 transcription factor gene, resultant double knock out mice lack all signs of SLE. Methods of screening for agents active against autoimmune diseases, for example SLE are provided. In vitro methods include screening for antagonists of OBF-1, screening for agents which inhibit binding of OBF-1 to oct-1 or oct-2, screening for agonists or antagonists of Aiolos protein and screening for agents which upregulate expression of Aiolos or downregulate expression of OBF-1. Also disclosed are methods of screening using knock-out mice and B cells from knock-out mice.
    Type: Application
    Filed: April 6, 2004
    Publication date: September 30, 2004
    Inventors: Patrick Daniel Matthias, Jian Sun